University of Washington's Neuro-Oncology Program to Investigate Cell Therapeutics' Drug Candidate OPAXIOâ¢ (Paclitaxel Poliglumex) plus Radiotherapy for Glioblastoma Multiforme, a Highly Malignant Brain Cancer